Literature DB >> 8102261

The role of lymphoid organs in the pathogenesis of HIV infection.

G Pantaleo1, C Graziosi, A S Fauci.   

Abstract

Following primary human immunodeficiency virus (HIV) infection, HIV disease is characterized by a prolonged period, usually lasting several years, of clinical latency. During this period viremia is generally very low or undetectable, the number of infected cells (i.e. viral burden) in the blood are very low, and the levels of viral replication in these cells are barely detectable. These findings have been interpreted as a reflection of a phase of inactive HIV disease during which time HIV replicates very slowly or its replicating ability is kept under control by effective HIV specific immune responses. However, during this period a general deterioration of immune function and progressive depletion of CD4+ T cells occur; the inevitable outcome is clinically apparent disease. In the present article, we describe a model of disease development in which HIV infection is both active and progressive in the lymphoid organs during the clinically latent period of HIV infection when there are few, if any, signs of disease activity in peripheral blood.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8102261     DOI: 10.1006/smim.1993.1019

Source DB:  PubMed          Journal:  Semin Immunol        ISSN: 1044-5323            Impact factor:   11.130


  20 in total

1.  Expansion of pre-existing, lymph node-localized CD8+ T cells during supervised treatment interruptions in chronic HIV-1 infection.

Authors:  Marcus Altfeld; Jan van Lunzen; Nicole Frahm; Xu G Yu; Claus Schneider; Robert L Eldridge; Margaret E Feeney; Dirk Meyer-Olson; Hans-Juergen Stellbrink; Bruce D Walker
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

Review 2.  Clinical use of quantitative molecular methods in studying human immunodeficiency virus type 1 infection.

Authors:  M Clementi; S Menzo; P Bagnarelli; A Valenza; S Paolucci; R Sampaolesi; A Manzin; P E Varaldo
Journal:  Clin Microbiol Rev       Date:  1996-04       Impact factor: 26.132

3.  Oxadiazols: a new class of rationally designed anti-human immunodeficiency virus compounds targeting the nuclear localization signal of the viral matrix protein.

Authors:  Omar Haffar; Larisa Dubrovsky; Richard Lowe; Reem Berro; Fatah Kashanchi; Jeffrey Godden; Christophe Vanpouille; Jürgen Bajorath; Michael Bukrinsky
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

4.  Early induction of polyfunctional simian immunodeficiency virus (SIV)-specific T lymphocytes and rapid disappearance of SIV from lymph nodes of sooty mangabeys during primary infection.

Authors:  Mareike Meythaler; Zichun Wang; Amanda Martinot; Sarah Pryputniewicz; Melissa Kasheta; Harold M McClure; Shawn P O'Neil; Amitinder Kaur
Journal:  J Immunol       Date:  2011-03-25       Impact factor: 5.422

5.  Dynamics and modulation of human immunodeficiency virus type 1 transcripts in vitro and in vivo.

Authors:  P Bagnarelli; A Valenza; S Menzo; R Sampaolesi; P E Varaldo; L Butini; M Montroni; C F Perno; S Aquaro; D Mathez; J Leibowitch; C Balotta; M Clementi
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

6.  Differential pathogenesis of primary CCR5-using human immunodeficiency virus type 1 isolates in ex vivo human lymphoid tissue.

Authors:  Ingrid Karlsson; Jean-Charles Grivel; Silvia Sihui Chen; Anders Karlsson; Jan Albert; Eva Maria Fenyö; Leonid B Margolis
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

7.  Phenotypic and functional changes in peripheral blood monocytes during progression of human immunodeficiency virus infection. Effects of soluble immune complexes, cytokines, subcellular particulates from apoptotic cells, and HIV-1-encoded proteins on monocytes phagocytic function, oxidative burst, transendothelial migration, and cell surface phenotype.

Authors:  J Trial; H H Birdsall; J A Hallum; M L Crane; M C Rodriguez-Barradas; A L de Jong; B Krishnan; C E Lacke; C G Figdor; R D Rossen
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

8.  Statin compounds reduce human immunodeficiency virus type 1 replication by preventing the interaction between virion-associated host intercellular adhesion molecule 1 and its natural cell surface ligand LFA-1.

Authors:  Jean-François Giguère; Michel J Tremblay
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

Review 9.  HIV-associated chronic immune activation.

Authors:  Mirko Paiardini; Michaela Müller-Trutwin
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

Review 10.  The role of collagen deposition in depleting CD4+ T cells and limiting reconstitution in HIV-1 and SIV infections through damage to the secondary lymphoid organ niche.

Authors:  Jacob D Estes; Ashley T Haase; Timothy W Schacker
Journal:  Semin Immunol       Date:  2008-07-02       Impact factor: 11.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.